Industry News
Pharmaceutical Industry News

The “Serve Up Protection”…
The "Serve Up Protection" Nuvaxovid education campaign will take place on and off the court, Sanofi said.
WuXi AppTec’s Ke Chen discusses…
WuXi AppTec’s Ke Chen discusses trends reshaping API manufacturing – while diligence, understanding and controlling the process remains the cornerstone
Akeso and Summit’s ivonescimab…
Akeso and Summit’s ivonescimab reduced the risk of death by 27% compared with Keytruda in the phase 3 Harmoni-2 trial in first-line, PD-L1-positive non-small cell lung cancer, with particularly strong data in the PD-L1-high group.
Bayer has won first-line approval…
Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med
The 60-second ad sees…
The 60-second ad sees "Yellowstone" actor Kevin Costner doing the math on the benefits of early cancer detection with Caris' Caris Detect blood test.
With a phase 3 win now fleshed out…
With a phase 3 win now fleshed out and an FDA filing recently submitted, BioMarin is advancing expansion plans for Voxzogo, looking to extend the dwarfism drug’s reach as it faces new pressure in its
Merck continues sweeping staff…
Merck continues sweeping staff reductions, laying off 54 at its Rahway headquarters. The staff changes are set to take effect in December and January.
As drug discovery is…
As drug discovery is revolutionized by AI, the machinery built to get life-saving medicines to market remains trapped in a different era. Here’s how we solve that.
In a stabilizing move, the…
In a stabilizing move, the Department of Health and Human Services announced Tuesday afternoon that it has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of CDER and CBER, respectively—to
RFK Jr. Promised Children’s Health Reforms. Here’s How He Did.
A year after the Trump administration laid out its plan to improve the health of American children, we examine where those efforts stand.
Exclusive insights from the…
Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and patient-focused drug development.
Spying a “golden decade”…
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar capabilities in the coming years.
While Amgen gave no numerical…
While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival
Shifts in drug pricing and market…
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for years to come, a survey of industry leaders found.
Novo Nordisk has reported a phase…
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after receiving the GLP-1 drug for 68 weeks.
In a rare divergence from its own…
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new treatment paradigm for molecular-guided
Roche has retained its status as…
Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate reputation rankings.
Belgian biopharma UCB is seeking…
Belgian biopharma UCB is seeking to boost awareness of what epilepsy looks like to patients, literally, with a new campaign using art to tell their stories.
Early Data Indicates an A.I.-Generated Drug Could Slow Aging
Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.
Ardelyx is running a new ad…
Ardelyx is running a new ad campaign for its irritable bowel syndrome with constipation drug, Ibsrela, across connected TV.


